Regeneron Pharmaceuticals (REGN) Net Income towards Common Stockholders (2009 - 2026)

Regeneron Pharmaceuticals' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $727.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 10.08% year-over-year to $727.2 million; the TTM figure through Mar 2026 stood at $4.4 billion (down 1.69% YoY), while the FY2025 annual figure was $4.5 billion, up 2.09% from the prior year.
• Net Income towards Common Stockholders was $727.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from $844.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.5 billion in Q3 2025 to a low of $722.0 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged $1.1 billion across 5 years, with a median of $973.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 72.5% in 2022, then soared 47.9% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $1.2 billion in 2022, then retreated by 3.13% to $1.2 billion in 2023, then decreased by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025, then retreated by 13.9% to $727.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $727.2 million (Q1 2026), $844.6 million (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.